Latest Articles

Publication Date
Beyond the Mass Effect: Decoupling Endometrioma Size and Bilaterality from Ovarian Reserve Depletion.

Ovarian endometriomas are commonly assessed according to cyst size and laterality, anatomical features that have long been regarded as indicators of disease severity and potential ovarian compromise. Consequently, these characteristics …

Published: Aug. 9, 2026, midnight
Targeting the IL-17C-M2 macrophage axis ameliorates fibrosis in endometriosis through MAPK/ERK signaling.

Endometriosis is characterized by inflammation and fibrosis, in which cytokines and cytokine-macrophage interactions serve as critical mediators. However, the specific mechanisms that initiate the fibrotic cascade in endometriosis remain poorly …

Published: Aug. 5, 2026, midnight
Low-energy extracorporeal shock wave therapy is associated with reduced inflammation and fibrosis in an E2-induced rat model of endometriosis and remains effective under menopause-mimicking conditions.

Endometriosis is an estrogen-dependent inflammatory disorder marked by ectopic lesions, chronic pelvic inflammation, and frequent recurrence. Extracorporeal shock wave therapy (ESWT) is a non-invasive modality with anti-inflammatory and regenerative potential, …

Published: Aug. 3, 2026, midnight
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - Fierce Pharma

Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis Fierce Pharma

Published: July 31, 2026, 2 p.m.
Clinical Outcomes of Uterine Artery Embolization in Adenomyosis With and Without Coexisting Uterine Fibroids or Ovarian Endometrioma: A Retrospective Clinical Analysis.

Uterine artery embolization (UAE) is a minimally invasive therapeutic option for adenomyosis (AM). However, its clinical effectiveness in patients with comorbid gynecologic disorders remains unclear. This study aimed to evaluate …

Published: July 31, 2026, midnight
Nanomaterial Platforms for Endometriosis: A Systematic Review.

Endometriosis (EM) is a chronic, estrogen-dependent inflammatory disease affecting approximately 10% of women of reproductive age worldwide, causing debilitating pelvic pain, infertility, and substantially impaired quality of life. Conventional hormonal …

Published: July 30, 2026, midnight
Exploring New Treatment Strategies for Endometriosis-Narrative Review.

The pharmacological treatment of endometriosis using SPRMs requires improvement. The pure PR-agonist dienogest (DNG), a clinically established progestin, can serve as a reference compound for comparison. Its efficacy and safety …

Published: July 28, 2026, midnight
Woman with fibroid the size of a large mango felt forced to go private due to NHS waiting list - AOL.com

Woman with fibroid the size of a large mango felt forced to go private due to NHS waiting list AOL.com

Published: July 26, 2026, 1:47 p.m.
Inflammation, Estrogen, and Matrix Remodeling in Female Reproductive Health: From Crosstalk Mechanisms to Translational Diagnostics.

The female reproductive system is a hormonally driven, immune-active, and structurally dynamic system in which estrogen signaling, inflammation, and extracellular matrix (ECM) remodeling interact to support essential reproductive processes. Cyclical …

Published: July 24, 2026, midnight
The Therapeutic Role of Dienogest in Endometriosis-Associated Pain: From Basics to Clinics.

The most common symptom of endometriosis is pain. The pathogenesis of endometriosis-associated pain remains unclear. In this review, we illustrate the pathogenesis of endometriosis-associated pain and the mechanisms of dienogest …

Published: July 23, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!